ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO986

Empagliflozin Attenuates Renal Fibrosis Through the DsbA-L-CAS-STING Pathway in Unilateral Ureteral Obstruction Model

Session Information

  • CKD: Pathobiology - I
    November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2203 CKD (Non-Dialysis): Mechanisms


  • Cho, Junghyun, Soonchunhyang University Hospital, Seoul, Korea (the Republic of)
  • Chung, Eui Suk, Soonchunhyang University Hospital, Seoul, Korea (the Republic of)
  • Lee, Haekyung, Soonchunhyang University Hospital, Seoul, Korea (the Republic of)
  • Kwon, Soon hyo, Soonchunhyang University Hospital, Seoul, Korea (the Republic of)

Chronic kidney disease (CKD) is associated with an increase in morbidity and mortality. Renal fibrosis is a common pathway leading to the progression of CKD. Recent studies have reported an improvement of CKD with use of sodium glucose cotransport 2 inhibitors (SGLT2i) in both patients with DM and those without it. However, the mechanism of SGLT2i’s effect upon CKD has not been elucidated. In current study, we examined the effect of SGLT2i on renal fibrosis in rats caused by unilateral ureteral obstruction (UUO).


Sprague Dawley rats were randomly divided into two groups (each n=8). One group was treated by Empagliflozin after UUO induction while the other group was left untreated. Kidneys were harvested two weeks after UUO. We evaluated the mitochondrial damage pathway presumed to contribute to the inflammation.


UUO has resulted in marked renal fibrosis and triggered the activation of the cGAS-STING pathway. Empagliflozin has been shown to attenuate renal fibrosis and decrease the activation of the cCAS-STING pathway. The expression of disulfide-bond A oxidoreductase-like proteins (DsbA-L) was increased in the Empagliflozin group (Figure 1).


These findings suggest that SGLT2i attenuates the development of renal fibrosis via inhibition of mitochondrial damage.